Events Details
AbbVie revenue jumps 17.8 pct on higher demand for drug Humira
Monday, August 01, 2016
AbbVie Inc's quarterly net revenue jumped 17.8 percent, driven by demand for its top-selling treatment, Humira.
The company, which acquired cancer drug developer Stemcentrx, said net revenue rose to $6.45 billion in the second quarter ended June 30 from $5.48 billion, a year earlier.
Net profit increased to $1.61 billion, or 98 cents per share, from $1.37 billion, or 83 cents per share.
Source : reuters.com
